Why Driving Impairment Evaluation Is Becoming More Important In CNS Drug Development

Between 2018 and 2024, only four out of forty novel drugs meeting the FDA's criteria for dedicated driving studies actually underwent formal evaluation. The remaining 36 relied on generalized label warnings advising patients to refrain from driving until they knew how the drug affected them. This gap between guidance and practice has sponsors facing a growing number of regulatory questions, particularly as complex central nervous system and psychedelic therapies move into late-stage trials.

Understanding functional safety early in development helps teams avoid generalized warnings that undermine prescriber confidence. By utilizing validated driving simulators, sponsors can objectively measure reaction times, divided attention, and lane positioning in a controlled environment. This article breaks down recent compliance trends, examines the regulatory risks of vague labeling, and outlines how simulation data can sharpen clinical strategy.